Biomarker and Diagnostics Patents

Biomarker and diagnostics patents span molecular biology; genomics; proteomics; and digital pathology — with Illumina's sequencing platform monopoly being the single most important IP position in the field: MAJOR DIAGNOSTICS PATENT HOLDERS: ILLUMINA: 5,000+ patents; SEQUENCING BY SYNTHESIS (SBS): specific reversible terminator nucleotide chemistry (specific 3'-O-azidomethyl blocking group for specific fluorescent nucleotide analogue; specific enzymatic cleavage step for deblocking); specific flow cell surface chemistry (specific NHS ester + silanization for specific oligonucleotide attachment; specific cluster density optimization); specific two-color imaging for SBS with specific base encoding scheme (four bases with two fluorescent dyes — specific G dark + specific A bright1 + specific T bright2 + specific C bright1+bright2 encoding); specific optical system for specific flow cell imaging; GRAIL (ILLUMINA ACQUISITION $8B + FTC BLOCK): specific multi-cancer early detection (MCED) cfDNA methylation profiling (specific bisulfite conversion + specific CpG methylation pattern + specific ML classifier for tissue-of-origin inference); specific circulating cell-free DNA (cfDNA) fragment length profiling; ROCHE: 10,000+ diagnostics patents; PCR-based diagnostics; specific cobas platform; specific digital PCR ddPCR variant; specific HER2/ERBB2 IHC companion diagnostic for trastuzumab (Herceptin); specific KRAS mutation test; QIAGEN: 3,000+; specific DNA/RNA extraction chemistry (specific silica membrane + chaotropic salt; specific spin column); specific bioinformatics pipeline; BIOMERIEUX: 2,000+; specific BIOFIRE film array (specific PCR + specific multiplex respiratory pathogen panel); specific VITEK microbial identification; EXACT SCIENCES (COLOGUARD): specific stool DNA + hemoglobin test for colorectal cancer screening; specific methylation-based biomarker panel; GUARDANT HEALTH: 500+ patents; specific digital sequencing approach to cfDNA error suppression (specific duplex sequencing variant + specific background error model).

Liquid biopsy and cfDNA analysis are the most patent-active areas of diagnostics innovation — where the intersection of molecular biology; bioinformatics; and machine learning has produced genuinely novel technical inventions: LIQUID BIOPSY PATENT LANDSCAPE: cfDNA ANALYSIS TECHNOLOGY: SPECIFIC PATENTABLE LIQUID BIOPSY INNOVATIONS: cfDNA EXTRACTION: specific plasma preparation protocol (specific anticoagulant + tube type for specific cfDNA yield + integrity); specific size selection for cfDNA enrichment; ERROR SUPPRESSION: specific duplex sequencing (specific molecular tag design with specific complementary tag on both strands for specific error rate reduction); specific unique molecular identifier (UMI) design and consensus read calling algorithm (specific family size threshold + specific variant calling with specific background error model); SPECIFIC MUTATION DETECTION: specific digital error suppression algorithm combining specific UMI consensus + specific position-specific background model + specific strand bias filter + specific base quality model achieving specific sensitivity at specific cfDNA allele fraction; METHYLATION PROFILING: specific bisulfite conversion efficiency determination; specific CpG methylation pattern feature extraction from cfDNA; specific ML model for tissue-of-origin classification (specific WGBS feature set + specific classifier architecture with specific AUC on specific cancer types); cfDNA FRAGMENT ANALYSIS: specific fragment length distribution profiling for specific cancer type detection (specific nucleosome positioning signature in tumor-derived cfDNA); specific end motif analysis; GUARDANT360 / GUARDANT HEALTH: specific cfDNA error correction for ctDNA detection at <1% allele fraction; specific comprehensive genomic profiling (CGP) from blood; GRAIL GALLERI TEST: specific multi-cancer detection from cfDNA methylation; specific >50 cancer types from single draw; FOUNDATION MEDICINE FoundationOne Liquid CDx: FDA-approved liquid biopsy CGP; specific 324 gene panel; CANCER DIAGNOSTICS BROADLY: COMPANION DIAGNOSTICS: specific Roche PATHWAY/VENTANA IHC assay for specific protein biomarker (specific antibody clone + specific staining protocol + specific scoring algorithm for specific clinical cut-point); specific PD-L1 IHC assay for specific immune checkpoint inhibitor; specific FISH assay for specific gene amplification; PRECISION ONCOLOGY: TEMPUS: specific multimodal ML for clinical + genomic data; specific treatment recommendation algorithm; CARIS LIFE SCIENCES: specific MI Profile tumor profiling; specific TMB + MSI + PD-L1 integrated reporting.

The Supreme Court&apos;s Mayo Collaborative Services v. Prometheus Laboratories (2012) decision created the most significant challenge to diagnostic patent eligibility — and understanding its application is essential for any diagnostics patent strategy: MAYO V. PROMETHEUS (566 U.S. 66, 2012): FACTS: Prometheus claimed method of optimizing thiopurine drug treatment based on metabolite levels; doctors measuring metabolite + using correlation to adjust dose; SUPREME COURT HELD: patent ineligible because the claim was directed to a natural law (the relationship between metabolite level and clinical response); additional steps (administer drug; determine metabolite level; use correlation) were routine + conventional = not enough to transform natural law into patent-eligible invention; IMPACT ON DIAGNOSTICS PATENTS: WHAT FAILS AFTER MAYO: diagnostic method claims that simply: (1) detect a natural biomarker; and (2) correlate it to a disease state or treatment recommendation; without specific technically inventive steps beyond detection and correlation; EXAMPLES: claim to &apos;measuring BRCA1 mutation + concluding elevated cancer risk&apos; = natural correlation = ineligible; claim to &apos;measuring cfDNA methylation at specific loci + determining cancer presence&apos; = potentially ineligible without more; WHAT MAY SURVIVE AFTER MAYO: SPECIFIC NOVEL DETECTION CHEMISTRY: specific novel assay chemistry that enables new detection capability (specific novel antibody; specific novel probe; specific novel PCR primer + conditions achieving specific sensitivity/specificity improvement vs. prior art); SPECIFIC NOVEL BIOINFORMATICS: specific novel computational pipeline that transforms data in a non-obvious way (specific error suppression algorithm; specific ML model architecture for specific clinical classification + specific training approach + specific performance metric improvement); IMPROVED TECHNIQUE: claim to specific improved cfDNA extraction method + specific error suppression achieving specific sensitivity improvement at specific allele fraction = directed to technical improvement; FDA-CLEARED COMPANION DIAGNOSTICS: the regulatory pathway requires clinical validation that may help differentiate from prior art; § 101 SURVIVAL STRATEGIES: CLAIM DRAFTING AROUND MAYO: (1) emphasize the specific technical implementation (novel chemistry; novel algorithm) not just the diagnostic result; (2) include specific hardware or laboratory method elements that are not routine; (3) claim the specific technical improvement (lower error rate; higher sensitivity; faster turnaround) as the inventive concept; (4) avoid language that reads as &apos;observe natural phenomenon and draw conclusion&apos;;

Diagnostics startups must navigate both § 101 Mayo eligibility challenges and a landscape of large incumbents with foundational sequencing and assay patents — requiring careful and thoughtful IP strategy: DIAGNOSTICS STARTUP IP STRATEGY: THE FUNDAMENTAL TENSION: diagnostics innovation often involves discovering natural correlations (biomarker → disease) which are ineligible under Mayo; the patentable innovation must be in HOW you detect or analyze — not just WHAT you discover; FILE EARLY AND FILE OFTEN: diagnostics companies should file provisional patent applications before any publication or public disclosure (conference presentations; grant applications; collaboration agreements); a single publication before filing can destroy patent rights globally; LAYERED PROTECTION STRATEGY: LAYER 1 — SPECIFIC NOVEL DETECTION ASSAY: patent the specific chemistry (specific probe design; specific primer + extension conditions; specific antibody clone) that enables your biomarker detection with specific improvement over prior art; LAYER 2 — SPECIFIC BIOINFORMATICS ALGORITHM: patent the specific computational pipeline (specific error suppression; specific ML classifier architecture; specific variant calling with specific performance metric); LAYER 3 — SPECIFIC CLINICAL VALIDATION DATA: while data itself isn&apos;t patentable; claims to specific validated biomarker combination + specific clinical decision threshold + specific use in specific patient population may be patentable if not routine; LAYER 4 — FDA REGULATORY: the FDA cleared or approved assay is commercially protected; competitors must obtain their own clearance; trade secrets for specific biomarker panel composition + training data; WHEN § 101 IS A PROBLEM: CLAIM AROUND NATURAL PHENOMENON: add specific technical steps (novel extraction; novel amplification; novel error correction) that transform the claim from natural phenomenon + mental step into specific technical process; USE METHOD OF TREATMENT CLAIMS: sometimes a method of treating a patient based on specific test result (where the treatment is specific and non-obvious) is more eligible than pure diagnostic claim; KEY FTO CONSIDERATIONS: ILLUMINA: foundational SBS sequencing chemistry + flow cell + imaging; any NGS-based diagnostic must FTO Illumina; ROCHE: PCR-based diagnostics + IHC companion diagnostic; QIAGEN: nucleic acid extraction + bioinformatics; GUARDANT HEALTH: cfDNA error suppression + liquid biopsy; GRAIL: methylation-based MCED; LIFE TECHNOLOGIES/THERMO FISHER: PCR + probe chemistry (many TaqMan patents); ARIOSA DIAGNOSTICS (ROCHE): NIPS cfDNA; EXACT SCIENCES: stool DNA extraction + methylation; DIAGNOSTICS IP AS ACQUISITION TARGET: Foundation Medicine (Roche acquisition $2.4B 2018); Grail (Illumina; FTC blocked; then separated — still contested); strong IP in validated diagnostics = significant acquisition premium.